Life Science Leader Blogs

1. From Utrecht To Amsterdam — Day 3 Of The Netherlands’ Biopharma Press Tour — Part 2
   2/4/2019

   The Netherlands’ biopharma press tour concludes in Amsterdam with presentations (e.g., AIMM Therapeutics) and guided tours of the O2 building and the National Screening Laboratory (NSS) for Sanquin.

2. From Utrecht To Amsterdam — Day 3 Of The Netherlands’ Biopharma Press Tour — Part 1
   1/30/2019

   Day 3 of the Netherlands’ biopharma press tour begins with presentations at the Utrecht Science Park (USP).

3. The Board Meeting West — More Than Just A Pre-JPM Appetizer?
   1/16/2019

   Rob Wright provides insight into The Board Meeting West, a life sciences industry event for high-level biopharmaceutical executives serving on corporate boards, or hoping to do so in the near future.

4. There Is Value To Being At The Center Of The JPM Universe
   1/15/2019

   Rob Wright provides a bit of his perspective on the 37^th Annual J.P. Morgan Healthcare Conference.

5. From Radboud UMC To Pivot Park — Day 2 Of The Netherlands’ Biopharma Press Tour
   12/6/2018

   Rob Wright shares experiences from day two of recent press tour of the Netherlands’ biopharmaceutical industry.

6. CNS Summit 2018 Does Not Meet Expectations — It Exceeded Them
   11/16/2018

   Rob Wright shares what makes the CNS Summit the best conference he has ever attended.

7. The Netherlands — More Than Just The New Home Of The EMA
   11/1/2018

   What sets the Netherlands biopharma sector apart from the rest of the world? That’s what Chief Editor Rob Wright hoped to find out as he began his press tour of the country’s biopharma industry.

8. Can China Be Trusted?
   10/1/2018

   Rob Wright discusses China’s history of intellectual property (IP) theft, and wonders if the government-sponsored 10-year initiative, Made in China 2025 (MIC 2025), could exacerbate the problem.

9. The Future Of Biopharma — Netherlands Style
   9/18/2018

   Rob Wright shares what he looks forward to learning about during an upcoming press tour of the Netherlands, beyond the fact that the European Medicines Agency (EMA) will be relocating there in 2019.

10. What Mylan Could Learn About Accountability
    8/31/2018

    Mylan’s inability to adequately supply its EpiPen during the 2018 back-to-school time is the latest example of corporate leadership lacking accountability.